Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.4700 (-0.18%) ($5.3400 - $5.4700) on Fri. Jan. 29, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.54% (three month average) | RSI | 38 | Latest Price | $5.4700(-0.18%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -0.4% a day on average for past five trading days. | Weekly Trend | ADAP declines -4.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) PAVE(40%) BLOK(39%) XLB(38%) IGOV(86%) IFRA(48%) | Factors Impacting ADAP price | ADAP will decline at least -2.27% in a week (0% probabilities). TLT(-26%) VCIT(-19%) VXX(-18%) UUP(-8%) TIP(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.27% (StdDev 4.54%) | Hourly BBV | -0.1 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $5.74 | 5 Day Moving Average | $5.51(-0.73%) | 10 Day Moving Average | $5.59(-2.15%) | 20 Day Moving Average | $5.74(-4.7%) | To recent high | -12% | To recent low | 8.9% | Market Cap | $846m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |